EUVIMEDObjevte EUVIMED
Open access

Discovery of DCAF16 Binders for Targeted Protein Degradation

Miguel A Campos, Isabella A Riha, Chenlu Zhang, Chen Mozes iD, Karl A Scheidt iD, Xiaoyu Zhang iD

ACS Chemical Biology · 2025-02-21 · 20 (2) · 479-488

DOI: 10.1021/acschembio.4c00799 ↗

At a glance

Journal article in ACS Chemical Biology, published online on 2025-01-30. Written by Miguel A Campos and 5 co-authors. Institution: Department of Chemistry, Northwestern University, Evanston, Illinois 60208, United States. Major MEDLINE topics: Proteolysis, Ubiquitin-Protein Ligases. Cited 27 times so far (Crossref); 51 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, NIGMS NIH HHS, National Science Foundation Graduate Research Fellowship Program.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Conventional small-molecule drugs primarily operate by inhibiting protein function, but this approach is limited when proteins lack well-defined ligand-binding pockets. Targeted protein degradation (TPD) offers an alternative approach by harnessing cellular degradation pathways to eliminate specific proteins. Recent studies have expanded the potential of TPD by identifying additional E3 ligases, with DCAF16 emerging as a promising candidate for facilitating protein degradation through both proteolysis-targeting chimera (PROTAC) and molecular glue mechanisms. In this study, we revisited a previously reported compound and discovered that it covalently binds to DCAF16. We further optimized it into a FKBP12-targeting PROTAC, MC-25B. This PROTAC engages DCAF16 at cysteines C177-179, leading to the degradation of nuclear-localized FKBP12. We further demonstrated the versatility of this DCAF16 recruiter by degrading additional endogenous proteins. Compared to the first-generation DCAF16-based PROTAC, which was derived from a fragment electrophile, this DCAF16 recruiter-based PROTAC exhibits improved proteome-wide selectivity.

Subjects

MeSH terms (MEDLINE)

ProteolysisUbiquitin-Protein LigasesHumansHEK293 CellsProtein BindingTacrolimus Binding Protein 1A

Substances

Tacrolimus Binding Protein 1AUbiquitin-Protein LigasesDCAF16 protein, human

Authors and institutions

  • Department of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.
  • Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois 60208, United States.
  • Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States.
  • International Institute for Nanotechnology, Northwestern University, Evanston, Illinois 60208, United States.
  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States.
  • Center for Human Immunobiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, United States.

ORCID profiles: Chen Mozes, Karl A Scheidt, Xiaoyu Zhang

Funding

  • NCI NIH HHS
  • NIGMS NIH HHS
  • National Science Foundation Graduate Research Fellowship Program
  • National Cancer Institute
  • Damon Runyon Cancer Research Foundation

Cite

APA

Campos, M. A., Riha, I. A., Zhang, C., Mozes, C., Scheidt, K. A., & Zhang, X. (2025). Discovery of DCAF16 Binders for Targeted Protein Degradation. ACS Chemical Biology, 20(2), 479-488. https://doi.org/10.1021/acschembio.4c00799

Vancouver

Campos MA, Riha IA, Zhang C, Mozes C, Scheidt KA, Zhang X. Discovery of DCAF16 Binders for Targeted Protein Degradation. ACS Chemical Biology. 2025;20(2):479-488. doi:10.1021/acschembio.4c00799

BibTeX
@article{Campos2025,
  author = {Campos, Miguel A and Riha, Isabella A and Zhang, Chenlu and Mozes, Chen and Scheidt, Karl A and Zhang, Xiaoyu},
  title = {Discovery of DCAF16 Binders for Targeted Protein Degradation},
  journal = {ACS Chemical Biology},
  year = {2025},
  volume = {20},
  number = {2},
  pages = {479--488},
  doi = {10.1021/acschembio.4c00799}
}
Start for free →